Navigation Links
Comprehensive Review of Cancer Immnunotherapies Published By CEL-SCI
Date:10/29/2007

VIENNA, Va., Oct. 29 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (Amex: CVM) announced today that it has published a very comprehensive review of cancer immunotherapies on its new website. The link is located in the top right hand corner of its home page at http://www.cel-sci.com .

Geert Kersten, Chief Executive Officer of CEL-SCI said, "Immunotherapy in the minds of many represents the future of cancer therapy. We have created an easy to navigate, interactive web based review that is designed to be helpful to doctors, patients as well as investors."

CEL-SCI Corporation is developing products that empower immune defenses. Its lead product is Multikine(R). In Phase II clinical trials Multikine was shown to be safe and well-tolerated, and to improve the patients' overall survival by 33% at a median of three and a half years following surgery. The U.S. Food and Drug Administration (FDA) gave the go-ahead for a Phase III clinical trial with Multikine in January 2007 and granted orphan drug status to Multikine as a neoadjuvant therapy of squamous cell carcinoma (cancer) of the head and neck in May 2007.

The Company has operations in Vienna, Virginia and Baltimore, Maryland. CEL-SCI's other products, which are currently in pre-clinical stage, have shown protection against a number of diseases in animal tests and are being tested against diseases associated with bio-defense.


'/>"/>
SOURCE CEL-SCI Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. A Comprehensive CD-ROM On HIV/AIDS Released By Center for HIV Information
2. ‘Comprehensive Sex Education’ Favored Against ‘Abstinence-Only’ Progams
3. Comprehensive Reforms to Move Toward Patient-Centered Care
4. Australia Proposes Comprehensive Plans to Protect Aboriginal Children from Sexual Abuse
5. UK Sports Clubs Failing to Run Comprehensive Health Checks on Professional Players
6. FDA may speed review of new drugs
7. Scientists review SARS
8. US Reviews Risks Of Tamiflu After 12 Children Die
9. Breast Cancer Examinations To Be Reviewed In Irish Hospitals
10. BioCryst’s Bird Flu Drug Enjoys Fast-Track Review By FD
11. A Sneak Preview of Human’s Susceptibility to Auto Immune Disease, Allergy, Asthm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... Vegas, Nevada (PRWEB) , ... October 13, 2017 , ... ... 7® Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD ... dose required and providing a CBD form that can be easily incorporated into liquid ...
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) ... a collection of specialty vendors and unique items from across the nation, this holiday-themed ... and wellness services offered by the VNA. The boutique will be open Saturday, ...
(Date:10/13/2017)... Fairfax, VA (PRWEB) , ... October 13, 2017 ... ... provider of DevOps and Agile Software Development, has been awarded a contract by ... (EATS) Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile ...
(Date:10/12/2017)... LA (PRWEB) , ... October 12, 2017 , ... Planet ... in the U.S., announced today its plans to open a flagship location in Covington, ... occupy the former Rooms To Go store next to Office Depot in the Holiday ...
(Date:10/12/2017)... Maryland (PRWEB) , ... October 12, 2017 , ... ... magnetic drug delivery system that we intend to develop to enable prevention of ... can lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... received FDA 510(k) clearance in May 2017 for its highly anticipated ... for endoscopy environments. An innovative secondary monitor solution, ZeroWire Mobile ... the improvement of patient outcomes, procedural efficiency, and the lowering of ... ... By ...
(Date:10/4/2017)... SEOUL, South Korea , Oct. 4, 2017 /PRNewswire/ ... launched its next-generation CPR training aide "cprCUBE" on Kickstarter. ... of chest compression during cardiac arrests with better efficiency ... patient-mannequins. It also offers real-time feedback on efficacy of ... The crowdfunding campaign has a goal to raise ...
(Date:10/2/2017)... -- Eli Lilly and Company (NYSE: LLY ) ... of 2017 on Tuesday, October 24, 2017. Lilly will ... the investment community and media to further detail the ... begin at 9 a.m. Eastern time. Investors, media and ... the conference call through a link that will be ...
Breaking Medicine Technology: